LingSense Bio Debuts in Silicon Valley With Advanced CGM & Wearable Dynamic Blood Pressure Technology

While the global digital health industry remains focused on specification-driven competition and fragmented use cases, LingSense Bio, a rising Chinese medtech innovator, chose Silicon Valley as the stage to present its answer.

At the “BEYOND SLEEP: THE STAREEP PREMIERE” global launch event, LingSense Bio, official medical health partner of smart sleep brand Stareep, made its international debut, introducing a comprehensive, closed-loop health management solution that integrates hardware, software, and AI services. This innovation aims to redefine healthcare standards for billions of chronic disease patients worldwide.

LingSense Bio’s wearable product lineup made a stunning debut

The LingSense Bio Ecosystem Ushers in an All in One AI Era of Seamless Monitoring

With the global chronic disease management market expanding rapidly into a trillion-dollar industry, Faris Li, Head of Product at LingSense Bio, delivered a keynote speech titled “Redefining Health Monitoring with Healthcare AI Wearables.” His assessment was direct: “Hardware alone cannot solve the challenges of chronic disease management. Without AI-driven intervention, health data is just a pile of numbers.”

Faris highlighted that while over 626 million people suffer from cardiovascular diseases and 830 million live with diabetes globally, continuous glucose monitoring (CGM) penetration among type 2 diabetes patients remains below 10%. Furthermore, dynamic blood pressure monitoring has long been constrained by traditional cuff-based devices. “Patients need unobtrusive, continuous, and precise monitoring, not fragmented occasional readings,” Faris emphasized. The future of medical-grade wearables, he noted, lies in two key trends: multi-parameter “All-in-One” integration and deep AI embedding from edge to platform.

To address these needs, LingSense Bio has developed a product matrix. Faris Li showcased two groundbreaking core hardware innovations:

Continuous Glucose Monitor (CGM): Boasting an industry-leading MARD (Mean Absolute Relative Difference) of under 8.0%, rivaling top-tier global brands.

Wearable dynamic Blood Pressure Monitor (dBP): The world’s first wearable dBP powered by Tonoarteriography (TAG) technology, developed by Professor Yuan-Ting Zhang’s team, delivering medical-grade continuous blood pressure tracking.

LingSense Bio also introduced LingWatch Pro, a smart watch with dynamic blood pressure monitoring; LingRing Nexus R1, a smart ring integrating non-invasive blood glucose trend monitoring, PPG, blood oxygen, temperature, and heart rate variability (HRV) monitoring;  and LingCare SpringMini, a portable oxygen concentrator designed to provide stable oxygen supply at altitudes of up to 6,000 meters.

These devices function as specialized physiological sensors that stream data into the LingSense Chronic Disease Management Platform, forming a closed-loop ecosystem covering glucose, blood pressure, blood oxygen, and ECG.

Faris Li delivered a keynote speech titled “Redefining Health Monitoring with Healthcare AI Wearables.”

Professor Yuan-Ting Zhang: Three Decades of Cuffless Innovation Reach Industrial Standard Moment

At the event, Professor Yuan-Ting Zhang, a Fellow of the International Academy for Medical and Biological Engineering, delivered a presentation titled “AI-Empowered Tonoarteriography for Digital Cardiovascular Health.” With over 30 years of pioneering research in cuffless blood pressure monitoring, Academician Zhang shared clinical insights and engineering philosophies that underscore the team’s forward-looking approach to digital cardiovascular health.

Professor Zhang pointed out that traditional blood pressure monitoring fails to capture critical nocturnal data. Clinical follow-ups from the Dublin Hypertension Clinic show that nighttime hypertension is highly correlated with a 5-year risk of cardiovascular mortality, and increased blood pressure variability serves as an independent warning sign. “However, traditional cuff-based devices cannot frequently inflate while a patient is sleeping without disrupting their rest,” Professor Zhang noted, highlighting the necessity of cuffless wearable technology. The deep learning models developed by his team for systolic and diastolic measurements have already achieved Grade A performance under IEEE, AAMI, and BHS standards.

Professor Yuan-Ting Zhang delivered a presentation titled “AI-Empowered Tonoarteriography for Digital Cardiovascular Health.”

The “dBP” solution represents a new era of 24/7 health management. By fusing physiological sensing, intelligent algorithms, and continuous data analysis, it offers a natural, low-burden monitoring experience. “The dBP focuses on long-term health trends rather than isolated readings,” Professor Zhang explained. “By analyzing continuous data streams, the system can provide valuable clinical insights for diagnosing masked hypertension, nocturnal anomalies, and evaluating chronic disease risks.”

Notably, Daniel Franklin, an Assistant Professor in the Institute of Biomedical Engineering at the University of Toronto, traveled to Silicon Valley as a specially invited international guest for the event. He participated in a session themed “Technology & Healthy Sleep,” where he engaged in an in-depth academic dialogue with fellow attendees. Known for his work in bio-integrated electronics and soft-matter photonics, Franklin offered an independent, clinically informed perspective on the event’s most anticipated innovation, the wearable dynamic blood pressure (dBP) monitoring technology.

Daniel Franklin participated in a session themed “Technology & Healthy Sleep” and shared in-depth academic insights

Data from LingSense Bio’s wearable product matrix, including CGM readings, ambulatory blood pressure data, blood oxygen saturation, and ECG signals, will be synchronized in real time to the LingSense Chronic Disease Management Platform. Built on LingSense Bio’s self-developed, medical-grade AI large model, the platform analyzes continuous health data and identifies potential risk patterns. It further incorporates Dr. PAI (Personalized AI Doctor), the world’s first hypertension intelligent management platform that combines a wearable dynamic blood pressure monitoring device, an AI health assistant avatar, and a large language model, developed by the team led by Professor Zhang. Together, they deliver a closed-loop experience spanning AI-powered consultation, health assessment, blood pressure pattern recognition, and personalized health management recommendations.

In January 2026, the U.S. Food and Drug Administration (FDA) officially released the draft guidance titled “Cuffless Non-invasive Blood Pressure Measuring Devices – Clinical Performance Testing and Evaluation,” marking a long-awaited standard for the industrialization of a technology nearly three decades in the making. Professor Zhang’s team has been deeply involved in the development of both the FDA draft guidance and the relevant IEEE standard; the IEEE standard led by his team has already been adopted by the FDA as a reference. “The world is embracing this standard, and LingSense is ready to be tested,” Professor Zhang said.

A China-Born Solution for Global Standards

As the Silicon Valley sun cast its glow over Stanford, LingSense Bio’s brand logo lit up across the giant screen. Without complicated regulatory language or excessive marketing rhetoric, LingSense had already delivered its message: connecting China’s precision with the world’s broader healthcare needs.

From CGM systems with an MARD below 8.0% to the medical-grade continuous wearable blood pressure monitor dBP, LingSense Bio is challenging a market long dominated by industry giants like Dexcom and Abbott. But for chronic disease patients around the world, the most meaningful takeaway from this launch may be what LingSense Bio President Zhifeng Peng put most simply: “Whether you live in a major city or a remote village, expert-level personal healthcare should not be a privilege.” This China-born solution, making its debut in Silicon Valley, is now accelerating onto the global stage.

Media Contact

Organization: LingSense Bio (Shenzhen) Technology Co., Ltd.

Contact Person: Ying Jixuan (Nancy)

Website: https://en.lingshee.com

Email:
yingjixuan@dreame.tech

City: Shanghai

Country:China

Release id:45276

The post LingSense Bio Debuts in Silicon Valley With Advanced CGM & Wearable Dynamic Blood Pressure Technology appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section